共 230 条
[1]
Walsh LJ(1996)Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study BMJ 313 344-346
[2]
Wong CA(2000)Use of oral corticosteroids in the United Kingdom QJM 93 105-111
[3]
Pringle M(2000)Use of oral corticosteroids and risk of fractures J Bone Miner Res 15 993-1000
[4]
Tattersfield AE(2005)Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients Arthritis Rheum 52 2485-2494
[5]
van Staa TP(1999)Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Arthritis Rheum 42 2309-2318
[6]
Leufkens HG(2000)Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study J Bone Miner Res 15 1006-1013
[7]
Abenhaim L(2007)Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study Osteoporos Int 18 25-34
[8]
Begaud B(2008)Relative effectiveness of osteoporosis drugs for preventing non-vertebral fracture Ann Intern Med 148 637-646
[9]
Zhang B(2009)RisedronatE and ALendronate intervention over three years (REALITY): minimal differences in fracture risk reduction Osteoporos Int 20 973-978
[10]
Cooper C(2009)Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study Bone 44 758-765